SearcharxivSearch

arXiv subjects

Xiangjun Kong

Publications and source records attributed to Xiangjun Kong.

2 recordsLinked to original sources

Deep Learning-based Single-Shot Composite Fringe Projection Profilometry with Pixel-Wise Uncertainty Quantification

Driven by the growing demand for high-speed 3D measurement in advanced manufacturing, optical metrology algorithms must deliver high accuracy and robustness under dynamic conditions. Fringe projection profilometry (FPP) offers high precision, yet the 2pi ambiguity of the wrapped phase means that conventional absolute phase recovery typically relies on multiple coded patterns, sacrificing temporal resolution. Deep learning-based composite FPP (CFPP) shows promise for single-shot phase recovery from a composite fringe, but limited interpretability makes it difficult to assess reconstruction reliability or trace error sources in the absence of ground truth. To address this, we propose HSURE-CFPP (Heteroscedastic Snapshot-ensemble Uncertainty-aware Ratio Estimation for CFPP). HSURE-CFPP predicts the numerator-denominator ratio used for wrapped-phase computation with a heteroscedastic snapshot-ensemble network, enabling ultra-fast 3D imaging from a single composite fringe and producing pixel-wise uncertainty maps for confidence assessment and unreliable-region identification. Specifically, a heteroscedastic likelihood jointly estimates pixel-wise noise variance to capture data uncertainty, while a snapshot ensemble quantifies model uncertainty via dispersion across snapshots, yielding total predictive uncertainty as an interpretable reliability measure. Experiments on static and dynamic scenes demonstrate that HSURE-CFPP achieves high-accuracy reconstruction at high speed and that the predicted uncertainty correlates well with reconstruction errors, providing a deployable quality-assessment mechanism for deep-learning-based FPP.

physics.optics

The Race of mRNA therapy: Evidence from Patent Landscape

mRNA therapy is gaining worldwide attention as an emerging therapeutic approach. The widespread use of mRNA vaccines during the COVID-19 outbreak has demonstrated the potential of mRNA therapy. As mRNA-based drugs have expanded and their indications have broadened, more patents for mRNA innovations have emerged. The global patent landscape for mRNA therapy has not yet been analyzed, indicating a research gap in need of filling, from new technology to productization. This study uses social network analysis with the patent quality assessment to investigate the temporal trends, citation relationship, and significant litigation for 16,101 mRNA therapy patents and summarizes the hot topics and potential future directions for this industry. The information obtained in this study not only may be utilized as a tool of knowledge for researchers in a comprehensive and integrated way but can also provide inspiration for efficient production methods for mRNA drugs. This study shows that infectious diseases and cancer are currently the primary applications for mRNA drugs. Emerging patent activity and lawsuits in this field are demonstrating that delivery technology remains one of the key challenges in the field and that drug-targeting research in combination with vector technology will be one of the major directions for the industry going forward. With significant funding, new organizations have developed novel delivery technologies in an attempt to break into the patent thicket established by companies such as Arbutus. The global mRNA therapeutic landscape is undergoing a multifaceted development pattern, and the monopoly of giant companies is being challenged.

stat.AP